通心络治疗急性脑梗塞疗效观察及作用分析

目的：了解通心络治疗急性脑梗死的效果并对其作用机制作初步探讨：方法：86例急性脑梗死患者随机分为通心络治疗试验组(43)和对照组(43)，采用改良爱丁堡-斯堪的纳维亚量表(mESSS)，日常生活活动量表(BI)对急性脑梗死患者通心络治疗组和对照组分别进行从入院至病后90天系列神经功能缺损评分及日常生活活动能力评分，并检测外周血IL-1水平。结果：通心络治疗组病后14、30、60、90d的神经功能缺损与对照组有显著性差异(减少值：mESSS，4．24，8．32，10．68，13．02，VS2．65，4．07，5．34，6．25)；病后60、90d日常生活活动能力评分通心络治疗组病比对照组高(BI：86．55，90．83，VS71．58，75．12)；病后14d时通心络治疗组外周血IL-1水平降低较对照组明显(11．75ng／ml，VS7．83ng/ml)，结论：通心络能改善急性脑梗死患者神经功能缺损及日常生活活动能力。

Observation of the Result of Tongxinluo Capsule for the Treatment of Acute Cerebral Infarction and Analysis of Its Mechanism

Objective:To observe the clinical result of Tongxinluo in treating acute cerebral infarction and analyzing its mechanism.Methods:Eighty-six patients suffered from acute cerebral infarction were divided randomly into Tongxinluo trial group and control group. Modified Edinberg-Scandinavian stroke scale(mESSS) was used to evaluate the neurological defects at admission,7th,14th day,1,2 and 3 months after stroke.Barth Index(BI) was used to evaluate the activity of daily living at 1,2 and 3 months after stroke.The plasma levels of IL-1 was measured at admission and 14 days after stroke. Results: Compared with those of the control group,the decrease of defect scores of neurological function on the day of 14,1,2 and 3 months after the onset of stroke were more significant(mESSS,4.24,8.32,10.68,and 13.02,VS 2.65,4.07,5.34 and 6.25 respectively,P<0.05);the scores of BI on 2 and 3 month were significantly increased(86.55 and 90.83 VS 71.58 and 75.12 respectively,P<0.05);The decrease of the plasma level of IL-1 had statistical significance compared with that of the control group(11.75 ng/ml VS 7.83 ng/ml).Conclusions Tongxinluo could reduce the defects neurological function and improve the prognosis in the patients having acute cerebral infarct.